Officinae Bio develops AI-powered platforms for mRNA and nucleic acid design and optimization, including the Mercurius platform that models biological dependencies to optimize UTRs, polyA tails, capping strategies, and chemical modifications for improved protein expression and tissue specificity. It offers custom mRNA design services such as RNAExpress, HITSmart, and LEADvantage bundles, along with DNA synthesis via the Vulcanus platform, supporting applications in gene therapy, cell therapy, and RNA therapeutics. The company, founded in 2020 and based in Venice, Italy, now operates as part of the Maravai LifeSciences ecosystem providing access to GMP manufacturing.
